Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Prevention of Acute Mountain Sickness in Normobaric Hypoxia
2021-000592-36Phase 4Terminated
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of erenumab in acute mountain sickness (AMS) and high altitude illness, sponsored by Universitätsmedizin Essen. Primary endpoint: Severity of acute mountain sickness. Started Jan 2023; status: terminated.
02
Drugs
erenumab
03
Conditions
acute mountain sickness (AMS)high altitude illness
Beyond the preview
Go deeper on 2021-000592-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000592-36.